Dmard
Sep 25, 2007 at 18:04
Nov 21, 2006 at 15:07
Photos »
/ 
Related News »
NEW YORK, May 23, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD ...
May 23, 2012 at 10:01 | Source: Yahoo Finance
A total of 98.6% of these patients received a prescription for DMARD therapy from the rheumatologist at the time of initial consultation. More than 99% of primary care providers reported that they would refer a patient with suspected RA to a ...
May 24, 2012 at 16:05 | Source: Medscape News
FDA approval would make tofacitinib the first new oral disease-modifying antirheumatic drug (DMARD) to be approved for rheumatoid arthritis in more than 10 years. Moreover, tofacitinib would be the first Janus kinase (JAK) inhibitor to be approved for ...
May 15, 2012 at 21:30 | Source: Zacks.com
This is a standard design for phase 2 trials in RA. MTX, a classic antifolate, is the most commonly prescribed disease modifying anti-rheumatic drug (DMARD) and is typically the first DMARD prescribed therapy for RA. However, the administration of mtx is ...
May 23, 2012 at 19:05 | Source: Seekingalpha.com
The current pipeline includes many small molecule drugs and biologic therapies, as well as the first oral Disease-Modifying Antirheumatic Drug (DMARD), Tofacitinib, by Pfizer. Patients may not even have to wait for these drugs to reach shelves, as 10% of ...
May 24, 2012 at 07:15 | Source: pressreleasepoint.com
Especially considering patients could be on the drug for five to 10 years, there was little long-term safety data for the 10mg dose, and that Pfizer's submission is for widespread use with patients eligible after having failed only one previous DMARD ...
May 11, 2012 at 17:25 | Source: Seekingalpha.com
compared to other groups who began with DMARD, has possibilities of biologic-free remission, further drug-free remission, lower cost of work loss and lower medical expenses. Smolen JS, Emery P. Infliximab: 12 years of experience. Arthritis Res ...
May 29, 2012 at 10:08 | Source: Medscape News
FDA approval would make tofacitinib the first new oral disease-modifying antirheumatic drug (DMARD) to be approved for rheumatoid arthritis in more than 10 years. Moreover, tofacitinib would be the first Janus kinase (JAK) inhibitor to be ...
May 15, 2012 at 21:16 | Source: Boston Globe
Concomitant Use with TNF antagonists: Concurrent therapy with ORENCIA and a biologic DMARD is not recommended. In controlled clinical trials, adult patients receiving concomitant intravenous ORENCIA and TNF antagonist therapy experienced more infections ...
May 14, 2012 at 19:51 | Source: Phramalive.com